Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AT13148||AT-13148|AT 13148||AKT Inhibitor (Pan) - ATP competitive 7 PKA Inhibitor 2||AT13148 is a small molecule ATP-competitive inhibitor of AGC kinases including AKT1, AKT2, AKT3, p70S6K (RPS6KB1), PKA (PRKACA), ROCK1, ROCK2, RSK1, and SGK3, which results in decreased growth of tumor cells (PMID: 22781553, PMID: 25840982, PMID: 32616501).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 pos PIK3CA mut||Her2-receptor positive breast cancer||sensitive||AT13148||Preclinical - Cell line xenograft||Actionable||In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).||22781553|
|Unknown unknown||stomach cancer||not applicable||AT13148||Preclinical||Actionable||In a preclinical study, AT13148 inhibited proliferation and induced apoptosis in gastric cancer cell lines in culture and inhibited tumor growth in a gastric cancer cell line xenograft model (PMID: 26828267).||26828267|
|Unknown unknown||melanoma||not applicable||AT13148||Preclinical||Actionable||In a preclinical study, AT13148 inhibited human melanoma cell motility in invasion assays in culture (PMID: 25840982).||25840982|
|PIK3CA mutant||breast cancer||sensitive||AT13148||Preclinical - Cell line xenograft||Actionable||In a preclinical study, a ERBB3 (HER3) positive breast cancer cell line xenograft model harboring a PIK3CA mutation was demonstrated decreased tumor growth when treated with AT13148 (PMID: 22781553).||22781553|
|Unknown unknown||Advanced Solid Tumor||not applicable||AT13148||Phase I||Actionable||In a Phase I trial, AT13148 treatment resulted in no complete or partial response in 51 patients with advanced solid tumors, and was not recommended for further development due to the unfavorable pharmacokinetic profile (PMID: 32616501).||32616501|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|